About Us
Zonsen PepLib Biotech Inc.
Zonsen PepLib Biotech Inc. is a high-tech biopharmaceutical enterprise that is dedicated to advancing global innovation in the discovery of new peptide drugs. Founded in September 2017, PepLib is headquartered in Zhuzhou, China, with a subsidiary in New Jersey, USA.
Our core peptide discovery platform is called Peptide Information Compression Technology (PICT), which consists of a diverse peptide library named ZSenithFive®, containing information on nearly half-billion peptides. The PICT platform is ideal for the discovery of functionally active peptides directly from cell-based and biochemical high-throughput screening (HTS) assays. In addition, we have developed 4 complimentary peptide discovery platforms: the Disulfide-rich Peptide Phage Display (DRP-PD) platform, the Animal Toxin Peptide Library Platform, the Nano-Cyclic Peptide Library Platform, and the Virtual Peptide Library Platform.
PepLib successfully raised 100 million yuan (USD 16 million) in Series Pre-A financing in 2019 and secured Series A financing of 220 million yuan (USD 35 million) in 2021. PepLib has been working towards Series Pre-IPO financing since August 2023. PepLib has more than 190 employees, and more than 80% of the workforce is made up of R&D personnel.
At PepLib, our main therapeutic area focus is oncology and cardiometabolic diseases. where oncology programs are driven by the development of peptide drug conjugates (PDCs) and peptide radionuclide conjugates (PRCs).
R&D Input
Accumulated R&D input of approximately 265 million yuan, with 600 million yuan expected to be invested in the next 3 years.
New Drug Milestone Service + Self-developed Pipelines.
.
Company Appearance
FLIPR tetra
Biotek Cytation10
Biotek Cytation5
Biotek Synergy neo2
PepLib aims to promote the development and accessibility of innovative peptide drugs, benefiting global patients and human health while keeping costs low.
Copyright©2023 Zonsen PepLib Biotech Inc. This website supports IPV6